

**PROTOCOL SIGNATURE PAGE**

**Protocol Title: Convalescent Plasma to Limit Coronavirus Associated Complications: A Randomized, Double-Blind, Controlled, Phase 2 Study Comparing the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 non-immune) Plasma Among Outpatients with Symptomatic COVID-19.**

Protocol Number: **CSSC-004**

Protocol Version/ Date: **v10.0/ October 20, 2021**

Sponsor Name: **Johns Hopkins University**

Declaration of Investigator

I confirm that I have read the above-mentioned protocol and its attachments. I agree to conduct the described trial in compliance with all stipulations of the protocol, regulations and ICH E6 Guideline for Good Clinical Practice (GCP).

Principal Investigator Signature: \_\_\_\_\_ Date \_\_\_\_\_